CD4 and cancer: We also applied NMFproj to scRNA-seq datasets of cross-tissue immune cells36 (Figure S6, POH: 0.560; Evar all: 0.332 in CD4+ T cells, supplemental note), pan-cancer tumor-infiltrating CD4+ T cells15 (Figure S4A, POH: 0.530; Evar all: 0.338, supplemental note), and mouse splenocytes37 (Figure S4B, POH: 0.394; Evar all: 0.146, supplemental note).